Campos Adrian I, Mulcahy Aoibhe, Thorp Jackson G, Wray Naomi R, Byrne Enda M, Lind Penelope A, Medland Sarah E, Martin Nicholas G, Hickie Ian B, Rentería Miguel E
Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD Australia.
Faculty of Medicine, The University of Queensland, Brisbane, QLD Australia.
Commun Med (Lond). 2021 Nov 9;1:45. doi: 10.1038/s43856-021-00046-8. eCollection 2021.
Major depression is one of the most disabling health conditions internationally. In recent years, new generation antidepressant medicines have become very widely prescribed. While these medicines are efficacious, side effects are common and frequently result in discontinuation of treatment. Compared with specific pharmacological properties of the different medications, the relevance of individual vulnerability is understudied.
We used data from the Australian Genetics of Depression Study to gain insights into the aetiology and genetic risk factors to antidepressant side effects. To this end, we employed structural equation modelling, polygenic risk scoring and regressions.
Here we show that participants reporting a specific side effect for one antidepressant are more likely to report the same side effect for other antidepressants, suggesting the presence of shared individual or pharmacological factors. Polygenic risk scores (PRS) for depression associated with side effects that overlapped with depressive symptoms, including suicidality and anxiety. Body Mass Index PRS are strongly associated with weight gain from all medications. PRS for headaches are associated with headaches from sertraline. Insomnia PRS show some evidence of predicting insomnia from amitriptyline and escitalopram.
Our results suggest a set of common factors underlying the risk for antidepressant side effects. These factors seem to be partly explained by genetic liability related to depression severity and the nature of the side effect. Future studies on the genetic aetiology of side effects will enable insights into their underlying mechanisms and the possibility of risk stratification and prophylaxis strategies.
重度抑郁症是全球最具致残性的健康问题之一。近年来,新一代抗抑郁药物的处方量已非常广泛。虽然这些药物有效,但副作用很常见,且经常导致治疗中断。与不同药物的特定药理特性相比,个体易感性的相关性研究较少。
我们使用了澳大利亚抑郁症遗传学研究的数据,以深入了解抗抑郁药物副作用的病因和遗传风险因素。为此,我们采用了结构方程模型、多基因风险评分和回归分析。
我们发现,报告一种抗抑郁药物有特定副作用的参与者,更有可能报告其他抗抑郁药物有相同的副作用,这表明存在共同的个体或药理因素。与副作用相关的抑郁症多基因风险评分(PRS)与抑郁症状重叠,包括自杀倾向和焦虑。体重指数PRS与所有药物导致的体重增加密切相关。头痛PRS与舍曲林引起的头痛有关。失眠PRS显示出一些证据,可预测阿米替林和艾司西酞普兰导致的失眠。
我们的结果表明,抗抑郁药物副作用风险存在一组共同因素。这些因素似乎部分可由与抑郁严重程度和副作用性质相关的遗传易感性来解释。未来关于副作用遗传病因的研究将有助于深入了解其潜在机制,以及进行风险分层和预防策略的可能性。